Disparities in the Use of SGLT2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Adults With CKD in the United States
Related Posts
Razavi AC, Bhatia HS, Dardari ZA, Mehta A, Nasir K, Blankstein R, Isiadinso I, Quyyumi AA, Vaccarino V, Fialkow JA, Khoury MJ, Coronado F, Budoff[...]
Surbhi S, Mallisetty Y, Shrestha P, Sumida K, Thomas F, Kalantar-Zadeh K, Kovesdy CP. Trends in Opioid Prescriptions and Short-term Mortality Outcomes for Patients With[...]
Cutting CC, Rose JA, Tukpah AC, Wada N, Nishino M, Kalra S, Moll MR, Cho MH, Silverman EK, Kinney GL, Rossiter HB, Bjarnadottir H, Gudmundsdottir[...]